Compliance with adjuvant treatment guidelines in endometrial cancer

Room for improvement in high risk patients

F.a. Eggink, C.h. Mom, D. Boll, N.P.M. Ezendam, R.F.P.M. Kruitwagen, J.M.A. Pijnenborg, M.A. van der Aa, H.W. Nijman

Research output: Contribution to journalArticleScientificpeer-review

Abstract

Objectives:
Compliance of physicians with guidelines has emerged as an important indicator for quality of care. We evaluated compliance of physicians with adjuvant therapy guidelines for endometrial cancer patients in the Netherlands in a population-based cohort over a period of 10years.

Methods:
Data from all patients diagnosed with endometrial cancer between 2005 and 2014, without residual tumor after surgical treatment, were extracted from the netherlands cancer registry (n=14,564). Figo stage, grade, tumor type and age were used to stratify patients into risk groups. Possible changes in compliance over time and impact of compliance on survival were assessed.

Results:
Patients were stratified into low/low-intermediate (52%), high-intermediate (21%) and high (20%) risk groups. Overall compliance with adjuvant therapy guidelines was 85%. Compliance was highest in patients with low/low-intermediate risk (98%, no adjuvant therapy indicated). The lowest compliance was determined in patients with high risk (61%, external beam radiotherapy with/without chemotherapy indicated). Within this group compliance decreased from 64% in 2005-2009 to 57% in 2010-2014. In high risk patients with figo stage III serous disease compliance was 55% (chemotherapy with/without radiotherapy indicated) and increased from 41% in 2005-2009 to 66% in 2010-2014.

Conclusion:
While compliance of physicians with adjuvant therapy guidelines is excellent in patients with low and low-intermediate risk, there is room for improvement in high risk endometrial cancer patients. Eagerly awaited results of ongoing randomized clinical trials may provide more definitive guidance regarding adjuvant therapy for high risk endometrial cancer patients.
Original languageEnglish
Pages (from-to)380-385
JournalGynecologic Oncology
Volume146
Issue number2
DOIs
Publication statusPublished - 1 Aug 2017

Fingerprint

Endometrial Neoplasms
Compliance
Physicians
Netherlands
Residual Neoplasm
Neoplasms

Cite this

Eggink, F. A., Mom, C. H., Boll, D., Ezendam, N. P. M., Kruitwagen, R. F. P. M., Pijnenborg, J. M. A., ... Nijman, H. W. (2017). Compliance with adjuvant treatment guidelines in endometrial cancer: Room for improvement in high risk patients. Gynecologic Oncology, 146(2), 380-385. https://doi.org/10.1016/j.ygyno.2017.05.025
Eggink, F.a. ; Mom, C.h. ; Boll, D. ; Ezendam, N.P.M. ; Kruitwagen, R.F.P.M. ; Pijnenborg, J.M.A. ; van der Aa, M.A. ; Nijman, H.W. / Compliance with adjuvant treatment guidelines in endometrial cancer : Room for improvement in high risk patients. In: Gynecologic Oncology. 2017 ; Vol. 146, No. 2. pp. 380-385.
@article{a17f2307272c4d5e9990a1f06f5808b9,
title = "Compliance with adjuvant treatment guidelines in endometrial cancer: Room for improvement in high risk patients",
abstract = "Objectives: Compliance of physicians with guidelines has emerged as an important indicator for quality of care. We evaluated compliance of physicians with adjuvant therapy guidelines for endometrial cancer patients in the Netherlands in a population-based cohort over a period of 10years.Methods: Data from all patients diagnosed with endometrial cancer between 2005 and 2014, without residual tumor after surgical treatment, were extracted from the netherlands cancer registry (n=14,564). Figo stage, grade, tumor type and age were used to stratify patients into risk groups. Possible changes in compliance over time and impact of compliance on survival were assessed.Results: Patients were stratified into low/low-intermediate (52{\%}), high-intermediate (21{\%}) and high (20{\%}) risk groups. Overall compliance with adjuvant therapy guidelines was 85{\%}. Compliance was highest in patients with low/low-intermediate risk (98{\%}, no adjuvant therapy indicated). The lowest compliance was determined in patients with high risk (61{\%}, external beam radiotherapy with/without chemotherapy indicated). Within this group compliance decreased from 64{\%} in 2005-2009 to 57{\%} in 2010-2014. In high risk patients with figo stage III serous disease compliance was 55{\%} (chemotherapy with/without radiotherapy indicated) and increased from 41{\%} in 2005-2009 to 66{\%} in 2010-2014.Conclusion: While compliance of physicians with adjuvant therapy guidelines is excellent in patients with low and low-intermediate risk, there is room for improvement in high risk endometrial cancer patients. Eagerly awaited results of ongoing randomized clinical trials may provide more definitive guidance regarding adjuvant therapy for high risk endometrial cancer patients.",
author = "F.a. Eggink and C.h. Mom and D. Boll and N.P.M. Ezendam and R.F.P.M. Kruitwagen and J.M.A. Pijnenborg and {van der Aa}, M.A. and H.W. Nijman",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.ygyno.2017.05.025",
language = "English",
volume = "146",
pages = "380--385",
journal = "Gynecologic Oncology: An International Journal",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

Eggink, FA, Mom, CH, Boll, D, Ezendam, NPM, Kruitwagen, RFPM, Pijnenborg, JMA, van der Aa, MA & Nijman, HW 2017, 'Compliance with adjuvant treatment guidelines in endometrial cancer: Room for improvement in high risk patients', Gynecologic Oncology, vol. 146, no. 2, pp. 380-385. https://doi.org/10.1016/j.ygyno.2017.05.025

Compliance with adjuvant treatment guidelines in endometrial cancer : Room for improvement in high risk patients. / Eggink, F.a.; Mom, C.h.; Boll, D.; Ezendam, N.P.M.; Kruitwagen, R.F.P.M.; Pijnenborg, J.M.A.; van der Aa, M.A.; Nijman, H.W.

In: Gynecologic Oncology, Vol. 146, No. 2, 01.08.2017, p. 380-385.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Compliance with adjuvant treatment guidelines in endometrial cancer

T2 - Room for improvement in high risk patients

AU - Eggink, F.a.

AU - Mom, C.h.

AU - Boll, D.

AU - Ezendam, N.P.M.

AU - Kruitwagen, R.F.P.M.

AU - Pijnenborg, J.M.A.

AU - van der Aa, M.A.

AU - Nijman, H.W.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Objectives: Compliance of physicians with guidelines has emerged as an important indicator for quality of care. We evaluated compliance of physicians with adjuvant therapy guidelines for endometrial cancer patients in the Netherlands in a population-based cohort over a period of 10years.Methods: Data from all patients diagnosed with endometrial cancer between 2005 and 2014, without residual tumor after surgical treatment, were extracted from the netherlands cancer registry (n=14,564). Figo stage, grade, tumor type and age were used to stratify patients into risk groups. Possible changes in compliance over time and impact of compliance on survival were assessed.Results: Patients were stratified into low/low-intermediate (52%), high-intermediate (21%) and high (20%) risk groups. Overall compliance with adjuvant therapy guidelines was 85%. Compliance was highest in patients with low/low-intermediate risk (98%, no adjuvant therapy indicated). The lowest compliance was determined in patients with high risk (61%, external beam radiotherapy with/without chemotherapy indicated). Within this group compliance decreased from 64% in 2005-2009 to 57% in 2010-2014. In high risk patients with figo stage III serous disease compliance was 55% (chemotherapy with/without radiotherapy indicated) and increased from 41% in 2005-2009 to 66% in 2010-2014.Conclusion: While compliance of physicians with adjuvant therapy guidelines is excellent in patients with low and low-intermediate risk, there is room for improvement in high risk endometrial cancer patients. Eagerly awaited results of ongoing randomized clinical trials may provide more definitive guidance regarding adjuvant therapy for high risk endometrial cancer patients.

AB - Objectives: Compliance of physicians with guidelines has emerged as an important indicator for quality of care. We evaluated compliance of physicians with adjuvant therapy guidelines for endometrial cancer patients in the Netherlands in a population-based cohort over a period of 10years.Methods: Data from all patients diagnosed with endometrial cancer between 2005 and 2014, without residual tumor after surgical treatment, were extracted from the netherlands cancer registry (n=14,564). Figo stage, grade, tumor type and age were used to stratify patients into risk groups. Possible changes in compliance over time and impact of compliance on survival were assessed.Results: Patients were stratified into low/low-intermediate (52%), high-intermediate (21%) and high (20%) risk groups. Overall compliance with adjuvant therapy guidelines was 85%. Compliance was highest in patients with low/low-intermediate risk (98%, no adjuvant therapy indicated). The lowest compliance was determined in patients with high risk (61%, external beam radiotherapy with/without chemotherapy indicated). Within this group compliance decreased from 64% in 2005-2009 to 57% in 2010-2014. In high risk patients with figo stage III serous disease compliance was 55% (chemotherapy with/without radiotherapy indicated) and increased from 41% in 2005-2009 to 66% in 2010-2014.Conclusion: While compliance of physicians with adjuvant therapy guidelines is excellent in patients with low and low-intermediate risk, there is room for improvement in high risk endometrial cancer patients. Eagerly awaited results of ongoing randomized clinical trials may provide more definitive guidance regarding adjuvant therapy for high risk endometrial cancer patients.

U2 - 10.1016/j.ygyno.2017.05.025

DO - 10.1016/j.ygyno.2017.05.025

M3 - Article

VL - 146

SP - 380

EP - 385

JO - Gynecologic Oncology: An International Journal

JF - Gynecologic Oncology: An International Journal

SN - 0090-8258

IS - 2

ER -